At the 23rd EHA Congress in Stockholm, investigators presented the latest developments in the treatment of myeloid malignancies. As an example, a novel FLT3 inhibitor for the first time demonstrated improved overall survival in AML. In addition, several presentations concerned excellent basic and translational research contributing to our understanding of the biology and pathophysiology of myeloid malignancies.
Click on the blocks below to see full presentation.
Age related clonal hematopoiesis
Understanding the biology of pediatric myelodysplasia and JMML